Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units

Wyeth is now a wholly owned subsidiary of Pfizer200 enrolled

Overview

To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Klebsiella pneumoniae in hematology and oncology units

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Gram-Positive Bacterial Infections Escherichia Coli Infections Klebsiella Infections

Interventions

piperacillin-tazobactamDRUG

Eligibility

Sex: ALLMin age: 15 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Eligible patients of either sex, 15 years of age or older * Patients who are admitted to the department of hematology and oncology * Provide written informed consent Exclusion Criteria: * Patients who have hypersensitivity to β-lactam antibiotics * Female who are pregnant or breast-feeding * Any underlying conditions or non-infectious diseases that will be ultimately fatal within 30 days

Locations (1)

Unnamed facility

Seoul, South Korea

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.